ITEMS IN AFP WITH KEYWORD:
Oct 15, 2019 Issue
Influenza Vaccination: Updated Recommendations from ACIP [Practice Guidelines]
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2019–2020 season.
Apr 1, 2019 Issue
HPV Vaccine for Prevention of High-Grade Precancerous Cervical Lesions [Medicine by the Numbers]
Data suggest the benefits of HPV vaccination for reducing precancerous lesions outweigh the potential harms. Find out more.
Women should receive the Tdap vaccine during pregnancy regardless of previous immunization history. Infants whose mothers received prenatal immunization had 50% fewer cases of pertussis compared with those whose mothers received postpartum immunization.
Feb 15, 2019 Issue
ACIP Approves 2019 Adult and Childhood/Adolescent Immunization Schedules [Practice Guidelines]
The 2019 adult and childhood/adolescent immunization schedules have been approved by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
Jan 1, 2019 Issue
Nausea in Pregnancy, Knee Osteoarthritis, Hormone Replacement Therapy, Shingles [AFP Clinical Answers]
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.
HPV vaccination in women 15 to 26 years of age prevents the development of cervical intraepithelial neoplasia (CIN) 2 and CIN 3 in women regardless of previous HPV exposure (number needed to treat [NNT] = 39). No serious adverse effects are associated with administration of the HPV vaccine.
Oct 15, 2018 Issue
Influenza Vaccination Recommendations for 2018-2019: Updates from ACIP [Practice Guidelines]
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2018–2019 season.
Recombinant zoster vaccine is a relatively new shingles vaccine that has been shown to have greater effectiveness and protection than the existing live vaccine. Local and systemic adverse effects may occur after administration, but have been shown to resolve within one to three days.
The American College of Physicians and Centers for Disease Control and Prevention highlights the consensus among these recommendations, with recent evidence, to develop a best practice advice statement for vaccination, screening, care, and treatment of patients at risk of or who currently have HBV infection.
The 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23) decreases the relative risk of community-acquired pneumonia in adults by 13%. The risk is reduced by 28% in the population that includes adults older than 65 years, those with lung disease, and those living in a nursing home.